Rybakowski J, Chłopocka-Woźniak M
Kliniki Psychiatrii Dorosłych AM w Poznaniu.
Psychiatr Pol. 1996 Sep-Oct;30(5):731-40.
In the beginning of 1960s, initial reports appeared pointing to a possibility of preventing depressive and manic recurrences in affective illness by means of long-term administration of lithium salts. Subsequent several years of controlled studies confirmed such prophylactic effect of lithium in affective illness beyond any doubt. Some patients in whom lithium administration was started in the beginning of 1970s may, by now, have received lithium for more than twenty years. The patient reported in the present paper, had began lithium treatment on April 1, 1971, after her third depressive episode since 1965. During 25 years of uninterrupted lithium carbonate administration in daily dose 1000 mg (for 5 years-750 mg) and with mean serum lithium concentration 0.6 mmol/l, the recurrences have not been observed, mental status was normal and professional (physician-ophthalmologist) and family functioning was good. Either somatic or mental side-effects have not occurred. Twenty five years of the patient's lithium treatment, was paralleled by important events for lithium therapy such as, i.a., autobiographies of prominent persons receiving lithium for porphylactic purposes, definition of a new category of psychotropic drugs (normothymic) with lithium as a prototype, establishing some mechanism of lithium action on intracellular transmission, discovery of antiviral and immunomodulatory effect of lithium as well as finding of decreased mortality of patients receiving long-term lithium therapy.
20世纪60年代初,最初有报告指出,通过长期服用锂盐有可能预防情感性疾病中的抑郁和躁狂复发。随后几年的对照研究毫无疑问地证实了锂在情感性疾病中的这种预防作用。一些在20世纪70年代初开始服用锂的患者,到现在可能已经服用锂超过20年了。本文所报道的患者在1965年以来第三次抑郁发作后,于1971年4月1日开始锂治疗。在连续25年每日服用1000毫克碳酸锂(5年中为750毫克)且平均血清锂浓度为0.6毫摩尔/升的情况下,未观察到复发,精神状态正常,职业(眼科医生)和家庭功能良好。未出现躯体或精神副作用。患者25年的锂治疗与锂治疗的一些重要事件同时发生,例如,一些知名人士接受锂预防性治疗的自传、以锂为原型定义了一类新的精神药物(心境稳定药)、确立了锂对细胞内传递的一些作用机制、发现了锂的抗病毒和免疫调节作用以及发现长期接受锂治疗的患者死亡率降低。